HK Stock Market Move | GIANT BIOGENE (02367) falls over 3% again, share price hits a new low since listing; Citi expects its full-year revenue growth target will be difficult to achieve.

date
15:07 19/11/2026
avatar
GMT Eight
GIANT BIOGENE (02367) fell over 3% again, with its intraday price touching HK$18.4, a new low since listing.
GIANT BIOGENE (02367) fell more than 3% again, touching HK$18.4 intraday, a new low since listing. As of press time, it is down 3.24% at HK$18.51, with turnover of HK$56.3929 million. On the news front, Citi issued a research report stating that GIANT BIOGENE's online sales performance during the Double 11 promotion was weaker than expected. The bank cut its profit forecasts by about 11% to 17%, lowered its target price from HK$38.4 to HK$29.3, maintained its "Buy" rating, but opened a 30-day negative catalyst watch. The bank believes management's target of 10% full-year revenue growth for 2026 will be difficult to achieve, and expects margin pressure to intensify amid potential downward operating leverage. In addition, on November 12, MSCI announced the results of its November 2026 quarterly index review, in which 38 stocks, including GIANT BIOGENE, were removed from the MSCI China Index. The changes will take effect after the close on November 30.